Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial.

Research output: Contribution to journalArticle

Abstract

Relative efficacy and toxicity of cyclophosphamide compared with ifosfamide are debatable. The Euro-EWING99-R1 trial asked whether cyclophosphamide may replace ifosfamide in combination with vincristine and dactinomycin (vincristine, dactinomycin, and cyclophosphamide [VAC] v vincristine, dactinomycin, and ifosfamide [VAI]) after an intensive induction chemotherapy containing vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in standard-risk localized disease (NCT00020566).

Details

Authors
  • Marie-Cécile Le Deley
  • Michael Paulussen
  • Ian Lewis
  • Bernadette Brennan
  • Andreas Ranft
  • Jeremy Whelan
  • Gwénaël Le Teuff
  • Jean Michon
  • Ruth Ladenstein
  • Perrine Marec-Bérard
  • Henk van den Berg
  • Lars Hjorth
  • Keith Wheatley
  • Ian Judson
  • Heribert Juergens
  • Alan Craft
  • Odile Oberlin
  • Uta Dirksen
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)2440-2448
JournalJournal of Clinical Oncology
Volume32
Issue number23
Publication statusPublished - 2014
Publication categoryResearch
Peer-reviewedYes